市場調查報告書
商品編碼
1023408

心臟再同步化治療(CRT)的全球市場:各產品類型、終端用戶、地區 - 趨勢分析、競爭、市場佔有率、預測(2017年∼2027年)

Global Cardiac Resynchronization Therapy Market; By Product Type, By End User, By Region Trend Analysis, Competitive Market Share & Forecast, 2017-2027

出版日期: | 出版商: Blueweave Consulting & Research Private Limited | 英文 200 Pages | 商品交期: 請詢問到貨日

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球心臟再同步化治療(CRT)市場,2020年估計為43億美元,預計從2021年到2027年的預測期間中以4.6%的年複合成長率成長,到2027年末達約62億美元。這樣的市場急速成長,起因於全球心血管疾病的盛行率高漲等。推動心血管再同步治療(CRT)市場的一個主要因素是全球心血管疾病的流行。

本報告提供全球心臟再同步化治療(CRT)市場調查,市場概要,市場成長要素及阻礙因素分析,市場機會,課題,各產品類型、終端用戶、地區的市場規模的變化與預測,主要地區詳細趨勢,競爭情形,新型冠狀病毒感染疾病(COVID-19)對市場的影響分析,主要企業簡介等彙整資訊。

目錄

第1章 調查組成架構

第2章 調查手法

第3章 摘要整理

第4章 全球心臟再同步化治療(CRT)市場洞察

  • 產業的價值鏈分析
  • DROC分析
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
  • 最近的開發趨勢/技術的進步
  • 法規的洞察

第5章 全球心臟再同步化治療(CRT)市場概要

  • 市場規模的變化與預測(2017年∼2027年)
  • 市場佔有率與預測
    • 各產品類型
      • 心臟去顫器
      • 心律調節器
      • 其他
    • 各終端用戶
      • 醫院、心臟中心
      • 門診外科中心
      • 其他
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美的心臟再同步化治療(CRT)市場

  • 市場規模的變化與預測(2017年∼2027年)
  • 市場佔有率與預測
    • 各產品類型
    • 各終端用戶
    • 各國
      • 美國
      • 加拿大

第7章 歐洲的心臟再同步化治療(CRT)市場

  • 市場規模的變化與預測(2017年∼2027年)
  • 市場佔有率與預測
    • 各產品類型
    • 各終端用戶
    • 各國
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
      • 俄羅斯
      • 其他

第8章 亞太地區(APAC)地區的心臟再同步化治療(CRT)市場

  • 市場規模的變化與預測(2017年∼2027年)
  • 市場佔有率與預測
    • 各產品類型
    • 各終端用戶
    • 各國
      • 日本
      • 中國
      • 印度
      • 韓國
      • 其他

第9章 南美的心臟再同步化治療(CRT)市場

  • 市場規模的變化與預測(2017年∼2027年)
  • 市場佔有率與預測
    • 各產品類型
    • 各終端用戶
    • 各國
      • 巴西
      • 阿根廷
      • 墨西哥
      • 其他

第10章 中東、非洲(MEA)的心臟再同步化治療(CRT)市場

  • 市場規模的變化與預測(2017年∼2027年)
  • 市場佔有率與預測
    • 各產品類型
    • 各終端用戶
    • 各國
      • 南非
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 土耳其
      • 其他

第11章 競爭情形

  • 主要企業產品一覽
  • 企業的市場佔有率分析(2020年)
  • 競爭基準:各運用指標
  • 競爭基準:各產品
  • 策略性開發趨勢

第12章 新型冠狀病毒感染疾病(COVID-19)對市場的影響

第13章 企業簡介

  • Abbott Laboratories
  • BIOTRONIK
  • Boston Scientific Corporation
  • Lepu Medical Technology Co. Ltd.
  • MEDICO S.p. A.
  • Medtronic Plc
  • Microport Scientific Corporation
  • Shree Pacetronix Ltd.
  • St. Jude Medical
  • LivaNova Plc.
  • Nihon Kohden Corporation
  • Koninklijke Philips N.V.
  • Japan Lifeline Co. Ltd.
  • Merit Medical System
  • Osypka Medical GmbH
  • OSCOR Inc.
  • Johnson & Johnson Services Inc.
  • Aetna Inc.
  • Elkem ASA
  • BG Medicine
  • Other Prominent Players.

第14章 主要策略的推薦事項

目錄
Product Code: BWC2116

Global Cardiac Resynchronization Therapy Market to Witness Significant Growth in Coming Years - Projected to Reach Worth USD 6.2 Billion in 2027

A recent study conducted by the strategic consulting and market research firm BlueWeave Consulting revealed that the Global Cardiac Resynchronization Therapy market was worth USD 4.3 Billion in 2020. The market is projected to grow at 4.6% CAGR during 2021-2027 (forecast period), earning around USD 6.2 Billion by the end of 2027. The expected surge in the market can be attributed to factors such as the increased prevalence of cardiovascular disorders worldwide. The concerning number of cardiac cases has been exacerbated due to the sedentary lifestyle of the majority of the population and the increasing elderly population worldwide. Patients that suffer from heart failure or cardiac arrhythmia are treated with cardiac resynchronization therapy.It works efficiently in about 7 out of 10 cases of heart failure. Patients have reported reductions in symptoms of heart failure after receiving CRT because it improves the heart's efficiency by increasing blood flow. However, a primary factor that inhibits theexpansion of the Global Cardiac Resynchronization Therapy market is its high price. Additionally, the lack of a proper reimbursement policy in many countries has also led to lower consumer adoption of cardiac resynchronization therapy.

The Rising Prevalance of Cardiac Cases Across the Globeis Favoring Market Growth

A major factor driving the cardiovascular resynchronization therapy (CRT) market is the prevalence of cardiovascular diseases across the globe.According to American Heart Association Research, heart disease is the leading cause of 1 out of 7 deaths in the U.S. Such concerning numbers have prompted end-users to incorporate the use of pacemakers and defibrillators in heart treatment procedures. It has become apparent over the past decade that the elderly population is more susceptible to cardiac anomalies, and people who lead sedentary lifestyles are more likely to develop high blood pressure.As per Population Reference Bureaus' Population Bulletin, by 2060, the total population share of the 65-and older age group will increase from 16% to 23%. This factor justifies the increase in cardiac cases, thereby driving the growth of the CRT market.

Advanced Product Launches Increasing Demand

In the year 2019, Microport Scientific Corporation launched the world's smallest transvenous pacemaker. It is MRI-friendly and empowers AF risk management. Technological innovations in the field of CRT devices have led to the growth and expansion of cardiac resynchronization therapy market applications.Many new product portfolios include pacemakers equipped with Bluetooth and data tracking technology. Pacemakers are also being introduced with the facility of remote patient monitoring. Such advancements have increased patient compliance and increased consumer adoption. For instance, Boston Scientific's Accolade pacemaker is newer, high-end product innovation. In addition to having the advantage of providing actionable data, it may also enable earlier intervention to avoid any dangerous situations.

Cardiac Resynchronization Therapy Pacemaker Segment Leading the Market.

The cardiac resynchronization therapy (CRT) market is categorized into CRT defibrillators, CRT pacemakers, and others by product types. The cardiac resynchronization therapy implantable pacemaker segment captured the largest market share in 2020 and is expected to grow further during the forecast period. This segment has an increased demand in the market as it provides a better and efficient solution to arrhythmic heart disorder. Pacemaker devices contain 2-3 leads and are placed within the left or right ventricle of cardiac patients with irregular heart rhythms.Moreover, favorable government regulations in many countries, such as India, have resulted in lower price margins for pacemaker devices. These factors have further expanded this segment of the cardiac resynchronization therapy market.

Impact of COVID-19

The cardiac resynchronization therapy market has faced a significant downfall during the COVID-19 pandemic. Immediately following the COVID outbreak, demand for CRT devices decreased worldwide.This is due to the fear of contracting a virus during surgery or an invasive procedure.Several studies suggest that patients with temporary pacemakers are susceptible to coronavirus due to their suppressed immunity.Also, due to a lack of resources and workforce, many surgical procedures, including implantation of CRT devices, have been delayed or canceled. This change of focus in the healthcare sector has negatively affected the market.Additionally, the supply and demand of the market have also been affected due to nationwide lockdowns, trade bans, and travel restrictions.

North America Highest Contributor to the Market

The Cardiac Resynchronization Therapy market is categorized into North America, Europe, the Asia-Pacific, Latin America, and the Middle East & Africa. Among these regions, North America dominated the market with the largest share in 2020. Market growth in this region has been driven by its high healthcare expenditures.This has resulted in the broad adoption of CRT device products among all end-users. Furthermore, the increased approvals of novel and sophisticated products by the US FDA have increased the market demand in North America.However, the Asia-Pacific region is predicted to be the most significant contributor to the cardiac resynchronization therapy market during the forecast period.In the Asia Pacific, one of the major factors driving the market growth is the high incidence of cardiac disease.The Global Burden of Disease reported that in India, the death rate due to cardiovascular disease is 272 per 1,00,000. Additionally, the growing awareness of cardiac health and public initiatives to improve healthcare has provided new opportunities to the Asia-Pacific region.

Competitive Landscape

The cardiac resynchronization therapy market is highly competitive, dominated by few established players. The key players operating in the market are Abbott Laboratories, BIOTRONIK, Boston Scientific Corporation, Lepu Medical Technology Co. Ltd., MEDICO S.p. A., Medtronic Plc, Microport Scientific Corporation,Shree Pacetronix Ltd., St. Jude Medical, LivaNova Plc.,Nihon Kohden Corporation, Koninklijke Philips N.V., Japan Lifeline Co. Ltd., Merit Medical System, Osypka Medical GmbH, OSCOR Inc., Johnson & Johnson Services Inc., Aetna Inc., Elkem ASA, BG Medicine, and other prominent players. The key market players have increased their investment in R&D, product launches, collaborations, and mergers & acquisitions as part of their market strategies.For instance, in January 2021, Boston Scientific Corporation announced its acquisition of Preventice Solutions.

Don't miss the business opportunity of the global cardiac resynchronization therapy market. Consult our analysts to gain crucial insights and facilitate your business growth.

The report's in-depth analysis provides information about growth potential, upcoming trends, and theglobal cardiac resynchronization therapy market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the global cardiac resynchronization therapy market ­ along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Research
  • 2.2. Quantitative Research
  • 2.3. Market Breakdown & Data Triangulation
    • 2.3.1. Primary & Secondary Research End-use Industry
    • 2.3.2. Secondary Research
    • 2.3.3. Primary Research
  • 2.4. Breakdown of Primary Research Respondents, By Region
  • 2.5. Assumption & Limitation

3. Executive Summary

4. Global Cardiac Resynchronization Therapy Market Insights

  • 4.1. Industry Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
    • 4.2.4. Challenges
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining End-use Industry of Suppliers
    • 4.3.2. Bargaining End-use Industry of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Intensity of Rivalry
  • 4.4. Recent Development/ Technological Advancement
  • 4.5. Regulatory Insights

5. Global Cardiac Resynchronization Therapy Market Overview

  • 5.1. Market Size & Forecast by Value, 2017-2027
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
      • 5.2.1.1. Cardiac Resynchronization Therapy Defibrillators
      • 5.2.1.2. Cardiac Resynchronization Therapy Pacemakers
      • 5.2.1.3. Others
    • 5.2.3. By End-User
      • 5.2.3.1. Hospitals & Cardiac Centres
      • 5.2.3.2. Ambulatory Surgery Centres
      • 5.2.3.3. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. Latin America
      • 5.2.4.5. Middle East and Africa

6. North Cardiac Resynchronization Therapy Market

  • 6.1. Market Size & Forecast by Value, 2017-2027
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End-User
    • 6.2.3. By Country
      • 6.2.3.1. U.S.
      • 6.2.3.2. Canada

7. Europe Cardiac Resynchronization Therapy Market

  • 7.1. Market Size & Forecast by Value, 2017-2027
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. France
      • 7.2.3.2. Germany
      • 7.2.3.3. Italy
      • 7.2.3.4. Spain
      • 7.2.3.5. U.K.
      • 7.2.3.6. Russia
      • 7.2.3.7. Rest of Europe

8. The Asia-Pacific (APAC) Cardiac Resynchronization Therapy Market

  • 8.1. Market Size & Forecast by Value, 2017-2027
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End-User
    • 8.2.3. By Country
      • 8.2.3.1. Japan
      • 8.2.3.2. China
      • 8.2.3.3. India
      • 8.2.3.4. South Korea
      • 8.2.3.5. Rest of APAC

9. Latin America Cardiac Resynchronization Therapy Market

  • 9.1. Market Size & Forecast by Value, 2017-2027
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End-User
    • 9.2.3. By Country
      • 9.2.3.1. Brazil
      • 9.2.3.2. Argentina
      • 9.2.3.3. Mexico
      • 9.2.3.4. Rest of Latin America

10. The Middle East & Africa (MEA) Cardiac Resynchronization Therapy Market

  • 10.1. Market Size & Forecast by Value, 2017-2027
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End-User
    • 10.2.3. By Country
      • 10.2.3.1. South Africa
      • 10.2.3.2. Saudi Arabia
      • 10.2.3.3. U.A.E.
      • 10.2.3.4. Turkey
      • 10.2.3.5. Rest of MEA

11. Competitive Landscape

  • 11.1. List of Key Players and their Offerings
  • 11.2. Company Market Share Analysis, 2020
  • 11.3. Competitive Benchmarking, By Operating Parameters
  • 11.4. Competitive Benchmarking, By Product Offerings
  • 11.5. Strategic Developments

12. Impact of Covid-19 across Cardiac Resynchronization Therapy Market

13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 13.1. Abbott Laboratories
  • 13.2. BIOTRONIK
  • 13.3. Boston Scientific Corporation
  • 13.4. Lepu Medical Technology Co. Ltd.
  • 13.5. MEDICO S.p. A.
  • 13.6. Medtronic Plc
  • 13.7. Microport Scientific Corporation
  • 13.8. Shree Pacetronix Ltd.
  • 13.9. St. Jude Medical
  • 13.10. LivaNova Plc.
  • 13.11. Nihon Kohden Corporation
  • 13.12. Koninklijke Philips N.V.
  • 13.13. Japan Lifeline Co. Ltd.
  • 13.14. Merit Medical System
  • 13.15. Osypka Medical GmbH
  • 13.16. OSCOR Inc.
  • 13.17. Johnson & Johnson Services Inc.
  • 13.18. Aetna Inc.
  • 13.19. Elkem ASA
  • 13.20. BG Medicine
  • 13.21. Other Prominent Players.

14. Key Strategic Recommendations